Skip to main navigation
Investor Relations
  • Home
  • About Us
    • Our Goal
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology Platform
    • Our Focus
    • The Challenge
    • Platform
  • Focus Areas
    • Pipeline
    • Osteoporosis
    • Hypoparathyroidism
  • Investors
    • Share Information
      • Share Chart
    • Email Alerts
    • Press Releases
    • SEC Filings
    • Investor Calendar
    • Corporate Governance
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Investor FAQS
      • Document Request
      • Email Alerts
  • Press Releases
  • Contact Us
Menu
Investor Relations
  • Home
  • About Us
    • Our Goal
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology Platform
    • Our Focus
    • The Challenge
    • Platform
  • Focus Areas
    • Pipeline
    • Osteoporosis
    • Hypoparathyroidism
  • Investors
    • Share Information
      • Share Chart
    • Email Alerts
    • Press Releases
    • SEC Filings
    • Investor Calendar
    • Corporate Governance
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Investor FAQS
      • Document Request
      • Email Alerts
  • Press Releases
  • Contact Us

SEC Filing Details

Document Details

Form
SCHEDULE 13G
Filing Date
Jan 6, 2025
Document Date
Jan 6, 2025
Form Description
SCHEDULE 13G - Description
Company
Entera Bio Ltd.
Issuer
Entera Bio Ltd.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Email Alerts
Investor FAQs
Contact IR
Logo

Hadassah Bio Park, 5th Floor |
Jerusalem Israel 9112002

info@enterabio.com

About Us
Company Profile
Strategy
Management Team
Board of Directors
Technology
Overview
Pipeline
Hypoparathyroidism
Osteoporosis
Bone Healing
News and Events
News
Events
Footer Bottom Social

Folow Us

  • Facebook
  • Twitter
  • Linkedin
  • Instagram

© 2025 Entera Bio Ltd. Privacy Policy